Continuing Metformin in Pregnancy Has Little Effect on Nonlive Birth
By Elana Gotkine HealthDay Reporter
TUESDAY, June 18, 2024 -- Continuing metformin and adding insulin in early pregnancy does not significantly alter the risk for nonlive birth or live birth with congenital malformations compared with switching to insulin monotherapy, according to a study published online June 18 in the Annals of Internal Medicine.
Yu-Han Chiu, M.D., Sc.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined the teratogenicity of metformin use in the first trimester of pregnancy in an observational cohort study of 12,489 pregnant women with pregestational type 2 diabetes receiving metformin monotherapy before the last menstrual period (LMP). Two treatment strategies were assessed: insulin monotherapy (discontinue metformin and initiate insulin within 90 days of LMP; 850 women) and insulin plus metformin (continue metformin and initiate insulin within 90 days of LMP; 1,557 women).
The researchers found that the estimated risk for nonlive birth was 32.7 and 34.3 percent under insulin monotherapy and insulin plus metformin, respectively (risk ratio, 1.02; 95 percent confidence interval, 1.01 to 1.04). The estimated risk for live birth with congenital malformations was 8.0 and 5.7 percent under insulin monotherapy and insulin plus metformin, respectively (risk ratio, 0.72; 95 percent confidence interval, 0.51 to 1.09).
"Current recommendations of switching from metformin to insulin before pregnancy for the management of type 2 diabetes in pregnancy based on teratogenicity concerns may require reconsideration," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
ADA: Bisphenol A Linked to Reduced Peripheral Insulin Sensitivity
THURSDAY, June 27, 2024 -- Bisphenol A (BPA) administration is associated with reduced peripheral insulin sensitivity among healthy adults, according to a study presented at the...
Dysbiosis in Phylogenetically Diverse Species Associated With Type 2 Diabetes
WEDNESDAY, June 26, 2024 -- The gut microbiome has a potential functional role in the pathogenesis of type 2 diabetes (T2D), according to a study published online June 25 in...
Intermittent Fasting Aids Early Diabetes Outcomes More Than Drugs
TUESDAY, June 25, 2024 -- Intermittent fasting may be a more effective intervention than drugs for people with early diabetes and either obesity or overweight, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.